Fenbendazole for Cancer: Does the Joe Tippens Protocol Work?

The Bottom Line

Fenbendazole is a benzimidazole anthelmintic used to treat parasitic worms in animals — it is not approved for human use. In the lab, it kills cancer cells through microtubule disruption, p53 activation, and glucose metabolism interference. A viral story (the "Joe Tippens Protocol") claimed dramatic cancer remission using fenbendazole alongside multiple other treatments. There are no human clinical trials establishing safety or efficacy for cancer. If you are interested in benzimidazoles for cancer, mebendazole is the human-approved alternative with actual clinical trial data and a known safety profile in humans.

What It Is

Fenbendazole ( marketed as Panacur C) is a broad-spectrum anthelmintic used in veterinary medicine to treat roundworms, hookworms, and other parasites in dogs and other animals. It works by binding to beta-tubulin in parasites, disrupting microtubule formation and starving the parasite of nutrients. It has been used safely in animals for decades. It is not FDA-approved for human consumption.

The Joe Tippens Story

In 2019, Joe Tippens, an Oklahoma man with stage IV small-cell lung cancer, claimed complete remission after taking fenbendazole alongside vitamin E, CBD oil, and curcumin. His oncologist reportedly told him he was "the only person in the world" with his cancer type to achieve complete remission. The story went viral, especially in South Korea, and spawned hundreds of "fenbendazole for cancer" Facebook groups and YouTube videos. Tippens was simultaneously receiving Keytruda (pembrolizumab), an immunotherapy drug, throughout his fenbendazole protocol — which he disclosed in later interviews. The degree to which fenbendazole (vs. the immunotherapy) contributed to his outcome is impossible to determine.

How It Works Against Cancer

Microtubule destabilization: Fenbendazole binds to beta-tubulin, disrupting microtubule assembly. This is the same mechanism (albeit weaker) as taxane chemotherapy drugs like paclitaxel and docetaxel. Cancer cells undergoing rapid division are particularly vulnerable to microtubule disruption.
p53 stabilization: Some studies suggest fenbendazole activates p53, the "guardian of the genome," promoting apoptosis in cancer cells with wild-type p53.
Glucose metabolism interference: Fenbendazole appears to disrupt glucose uptake and metabolism in cancer cells, compounding the metabolic stress from microtubule disruption.
Proteasome inhibition: Emerging evidence suggests fenbendazole may inhibit the proteasome, another established cancer drug target (bortezomib works this way).
HIF-1 alpha suppression: May inhibit hypoxia-inducible factor, reducing tumors' ability to adapt to low-oxygen environments.

The Evidence

In Vitro (Test Tube) Data — Strong

Multiple peer-reviewed papers have confirmed fenbendazole kills cancer cells in culture:

Dogra et al., Sci Rep 2018: Showed fenbendazole induced apoptosis in cancer cells via microtubule disruption, p53 stabilization, and metabolic interference. This is the most cited paper in the fenbendazole-for-cancer literature.
5-FU resistant colorectal cancer (PMC9437363, 2022): Fenbendazole showed activity even against chemotherapy-resistant cells.
Multiple cell lines tested: activity against colorectal, hepatocellular, ovarian, and lung cancer cell lines.

Animal Data — Moderate

The EMT6 mouse mammary tumor model showed fenbendazole had some antitumor activity (PMC3580766). However, animal models of single agents rarely translate to human efficacy, and the doses used in mice may not be achievable or tolerable in humans.

Human Clinical Trials — NONE

There are zero registered clinical trials of fenbendazole in cancer patients. No Phase I, II, or III trials. No safety data in humans at anticancer doses. This is the critical gap — the jump from "kills cancer in a dish and in mice" to "works in humans" is enormous and has defeated many promising-looking compounds.

Case Series (2025)

A 2025 case series (PMC12215191) described 3 patients who self-administered fenbendazole alongside multiple other supplements and treatments. One patient showed bone lesion regression after one year — but was simultaneously taking vitamin D, melatonin, berberine, curcumin, artemisinin, and cimetidine. The results are impossible to attribute to fenbendazole alone.

Evidence Grade: C — Early / Limited

The mechanism is real and interesting. The preclinical data is legitimate and peer-reviewed. But there are zero human clinical trials. The Joe Tippens story is compelling but confounded by concurrent immunotherapy. The benzimidazole class includes mebendazole, which IS approved for humans and has actual clinical trial data — making it a far more rational choice.

Fenbendazole vs. Mebendazole

If you are considering a benzimidazole for cancer, mebendazole is the evidence-backed choice:

FDA-approved for humans: Mebendazole has been used safely in humans for parasitic infections since the 1970s. Fenbendazole has no human safety data.
Clinical trials: Mebendazole has Phase I and Phase II RCT data in glioblastoma and colorectal cancer. Fenbendazole has none.
Crosses blood-brain barrier: Both mebendazole and fenbendazole appear to cross the BBB, but mebendazole's BBB penetration is better documented in human studies.
Mechanism: Both work through microtubule disruption, but mebendazole has additional well-characterized anticancer mechanisms (Hedgehog inhibition, VEGF).
Cost: Both are cheap generics. Mebendazole is approximately $5-15 for a treatment course.

Protocol Considerations

Joe Tippens Protocol (anecdotal): Fenbendazole 222mg (1g Panacur C packet) 3 days on / 4 days off, plus vitamin E 800 IU/day, CBD oil 25mg/day, curcumin 600mg/day
WARNING: These doses have never been studied in humans for cancer. Safety is unknown. The 3-days-on/4-days-off schedule was reportedly chosen to reduce liver toxicity in the original veterinary use.
Quality control: Veterinary fenbendazole products are not manufactured to human pharmaceutical standards

Risks

Not approved for human use: No human pharmacokinetic or safety data at anticancer doses
Liver toxicity: Elevated liver enzymes reported in some self-administering patients
Poor oral bioavailability: Variable absorption, especially from veterinary formulations
Drug interactions: CYP450 substrate — may interact with other medications
Delay of effective treatment: Choosing unproven alternatives over established therapy carries real risk

Our Assessment

Fenbendazole's anticancer mechanism is real and scientifically plausible. The lab data is legitimate. But it is a veterinary drug with no human clinical trial data. The viral Joe Tippens story is interesting but confounded by concurrent immunotherapy and multiple other supplements. If you are drawn to the benzimidazole approach — and there is reason to be, given mebendazole's more established evidence base — please consider mebendazole instead. It is human-approved, has actual clinical trial data, and carries a known safety profile. The difference in evidence quality between fenbendazole and mebendazole is not subtle.

Sources

Dogra et al. Sci Rep 2018;8:11926 — https://doi.org/10.1038/s41598-018-30158-6
PMC12215191 (2025 case series)
PMC9437363 — 5-FU resistant colorectal cancer (2022)
PMC3580766 — EMT6 mouse model
Anticancer Research 44(9):3725 (2024 review) — https://ar.iiarjournals.org/content/44/9/3725
PMC9650234 — Fenbendazole misinformation analysis